This was part of the conditions that allow an athlete to perform at the best level. But now with GLP-1 analogs, the paradigm has changed a little bit because you do not necessarily need to make that effort to control your weight and have this embedded as part of your regimen to perform at the highest level, Rabin explains
This may be explained by a relatively low trial drug exposure (76%) compared to other CVOTs, and that the trial had no run-in period and, therefore, had one of the highest discontinuation rates
We conduct thorough medication reviews to identify potential drug interactions, especially for patients managing diabetes, hypertension, or hyperlipidemia, ensuring safe and effective treatment
Oxyntomodulin: actions and role in diabetes
According to FDA labeling for Wegovy (semaglutide), patients should be evaluated after 12 weeks at the maintenance dose (2.4 mg weekly), with discontinuation considered if less than 5% body weight reduction has been achieved
Clinical trials are being run on combination therapies that can help preserve muscle massa big issue for GLP-1 usersand maybe even cut back on GI symptoms
